Dr. Jin Wang is Vice President of Clinical Development at K2 Therapeutics, where she leads global development strategies and supports investment, search and evaluation, and business development initiatives. With 15 years of drug development experience, Dr. Wang has directed programs spanning early to late phases, including globally approved Tislelizumab and Zanidatamab.
Before joining K2, Dr. Wang held senior leadership roles across global biopharma. At Gilead Sciences, she led clinical development for the APAC region. As Chief Medical Officer at Ablaze Pharmaceuticals, she advanced a radiopharmaceutical pipeline to IND-enabling stages prior to its acquisition by Bristol Myers Squibb. At BeiGene, she directed global development strategies and cross-functional teams for major oncology assets.
Her earlier career includes impactful contributions at Eli Lilly and IQVIA, as well as hands-on patient care at Shanghai Changzheng Hospital.
Dr. Wang holds an MD and PhD in Medicine and is board-certified in Medical Oncology.